Nalbuphine

CHEMBL895 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

357.4 g/mol

LogP

0.2

Phase

4

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

Peso Molecular

357,4000 g/mol

LogP

0,20

TPSA

73,20 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pain Management Non-Small Cell Lung Cancer Asthma Generalized Anxiety Disorder Insomnia Obesity Hypertension Breast Cancer Chronic Pain Heart Failure Leukemia

Mecanismo de Ação

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314

InChI

InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1

Molecular Formula

C21H27NO4

HBD / HBA

3 / 5

Ligações Rotacionáveis

2

Átomos Pesados

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Nalbuphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL895. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5311304. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Nalbuphine no PillFYI

Estrutura

Dados Rápidos

Fórmula: C21H27NO4

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.